VTGN · Vistagen Therapeutics, Inc.
$0.27
+0.00 (+0.49%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of August 14, 2026, the issuance date of the condensed consolidated financial statements as of and for the three months ended June 30, 2026, there is uncertainty about whether the Company's combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of these condensed consolidated financial statements and therefore the Company concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$11.88M
Shares
44.38M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Douglas J. Williamson, M.D. | director | Appointed | 2026-07-31 |
| Angel S. Angelov, M.D., MBA | Chief Medical Officer | Appointed | 2026-05-19 |
| Mary Rotunno | Board of Directors | Resigned | 2026-03-18 |
| Paul Edick | Board of Directors | Resigned | 2026-02-20 |
| Nick B. Tressler | principal financial and accounting officer | Appointed | 2025-12-03 |
| Nick B. Tressler | Chief Financial Officer and Treasurer | Appointed | 2025-12-03 |
| Paul R. Edick | director | Appointed | 2025-10-29 |
| Cynthia L. Anderson | Chief Financial Officer and principal financial and accounting officer | Resigned | 2025-09-15 |
| Elissa Cote | Chief Corporate Development Officer | Appointed | 2025-06-25 |
| Joshua Prince | Chief Operating Officer | Appointed | 2023-10-26 |
| Jerrold Dotson | Chief Financial Officer | Retired | 2023-08-22 |
| Cynthia Anderson | Chief Financial Officer | Appointed | 2023-08-22 |
| Mark A. Smith | Chief Medical Officer | Resigned | 2022-11-22 |
| H. Ralph Snodgrass | President and Chief Scientific Officer | Terminated | 2022-06-22 |
| Reid G. Adler | Chief Legal Officer | Appointed | 2022-05-03 |
Key facts
CIK
1411685
CUSIP
92840H400
13F (30d)
57 filings
56 filers
Visit website
Investor relations